Pelabresib

In this video, Lindsay A.M. Rein, MD, discussed the TRANSFORM-1 and MANIFEST-2 trials into combination therapies in myelofibrosis, both of which were presented at the ASH Annual Meeting and Exposition.

In this video, John Mascarenhas, MD, discussed the MANIFEST-2 study into combination therapies in myelofibrosis treatment, which was presented at the ASH Annual Meeting and Exposition.

In this video, Aaron T. Gerds, MD, MS, discussed the TRANSFORM-1 and MANIFEST-2 trials into combination therapies in myelofibrosis, both of which were presented at the ASH Annual Meeting and Exposition.

The combination of pelabresib plus ruxolitinib significantly increased the proportion of patients with myelofibrosis who achieved a clinically meaningful reduction in spleen volume, according to the agent’s manufacturer.

In this video, Aaron T. Gerds, MD, MS, discussed the backstory behind a study presented at ASCO Annual Meeting, examining the effect of the BET inhibitor pelabresib on patients with essential thrombocythemia.